These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 19855427)

  • 1. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.
    Wang L; de Zoeten EF; Greene MI; Hancock WW
    Nat Rev Drug Discov; 2009 Dec; 8(12):969-81. PubMed ID: 19855427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms.
    Beier UH; Wang L; Han R; Akimova T; Liu Y; Hancock WW
    Sci Signal; 2012 Jun; 5(229):ra45. PubMed ID: 22715468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone/protein deacetylase inhibitor therapy for enhancement of Foxp3+ T-regulatory cell function posttransplantation.
    Wang L; Beier UH; Akimova T; Dahiya S; Han R; Samanta A; Levine MH; Hancock WW
    Am J Transplant; 2018 Jul; 18(7):1596-1603. PubMed ID: 29603600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
    Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
    PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for HDAC inhibitor therapy in autoimmunity and transplantation.
    Hancock WW
    Handb Exp Pharmacol; 2011; 206():103-23. PubMed ID: 21879448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance.
    Wang L; Tao R; Hancock WW
    Immunol Cell Biol; 2009; 87(3):195-202. PubMed ID: 19172156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs.
    Akimova T; Ge G; Golovina T; Mikheeva T; Wang L; Riley JL; Hancock WW
    Clin Immunol; 2010 Sep; 136(3):348-63. PubMed ID: 20478744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of isoform-selective histone/protein deacetylase inhibitors improves Foxp3+ T-regulatory cell function.
    Beier UH; Wang L; Hancock WW
    Cell Cycle; 2012 Sep; 11(18):3351-2. PubMed ID: 22918251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells.
    de Zoeten EF; Wang L; Butler K; Beier UH; Akimova T; Sai H; Bradner JE; Mazitschek R; Kozikowski AP; Matthias P; Hancock WW
    Mol Cell Biol; 2011 May; 31(10):2066-78. PubMed ID: 21444725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells.
    Beier UH; Akimova T; Liu Y; Wang L; Hancock WW
    Curr Opin Immunol; 2011 Oct; 23(5):670-8. PubMed ID: 21798734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitors and transplantation.
    Tao R; de Zoeten EF; Ozkaynak E; Wang L; Li B; Greene MI; Wells AD; Hancock WW
    Curr Opin Immunol; 2007 Oct; 19(5):589-95. PubMed ID: 17719760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC inhibitor therapy in autoimmunity and transplantation.
    Hancock WW; Akimova T; Beier UH; Liu Y; Wang L
    Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i46-54. PubMed ID: 22460138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The attenuation of renal fibrosis by histone deacetylase inhibitors is associated with the plasticity of FOXP3
    Wu WP; Tsai YG; Lin TY; Wu MJ; Lin CY
    BMC Nephrol; 2017 Jul; 18(1):225. PubMed ID: 28693431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function.
    Huang J; Wang L; Dahiya S; Beier UH; Han R; Samanta A; Bergman J; Sotomayor EM; Seto E; Kozikowski AP; Hancock WW
    Sci Rep; 2017 Aug; 7(1):8626. PubMed ID: 28819166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deacetylase inhibition promotes the generation and function of regulatory T cells.
    Tao R; de Zoeten EF; Ozkaynak E; Chen C; Wang L; Porrett PM; Li B; Turka LA; Olson EN; Greene MI; Wells AD; Hancock WW
    Nat Med; 2007 Nov; 13(11):1299-307. PubMed ID: 17922010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease.
    Ratay ML; Balmert SC; Bassin EJ; Little SR
    Acta Biomater; 2018 Apr; 71():261-270. PubMed ID: 29526828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells.
    Kalin JH; Butler KV; Akimova T; Hancock WW; Kozikowski AP
    J Med Chem; 2012 Jan; 55(2):639-51. PubMed ID: 22165909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo.
    Glauben R; Sonnenberg E; Wetzel M; Mascagni P; Siegmund B
    J Biol Chem; 2014 Feb; 289(9):6142-51. PubMed ID: 24421314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells.
    Lopez-Pastrana J; Shao Y; Chernaya V; Wang H; Yang XF
    Transl Res; 2015 Jan; 165(1):221-40. PubMed ID: 25193380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans.
    Choi SW; Gatza E; Hou G; Sun Y; Whitfield J; Song Y; Oravecz-Wilson K; Tawara I; Dinarello CA; Reddy P
    Blood; 2015 Jan; 125(5):815-9. PubMed ID: 25428224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.